Indication

Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior lines of systemic therapies, at least one of them given for unresectable locally advanced or metastatic disease.

Medicine details

Medicine name:
sacituzumab govitecan (Trodelvy)
SMC ID:
SMC2466
Pharmaceutical company
Gilead Sciences Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
14 March 2022
SMC meeting date:
01 February 2022
Patient group submission deadline:
29 November 2021